Dr. Reddy’s Laboratories said the U.S. Securities and Exchange Commission has concluded its investigation into allegations of improper payments to healthcare professionals in Ukraine and other markets that could have violated U.S. anti-corruption laws, including the Foreign Corrupt Practices Act. In a letter dated Feb. 23, 2026, the SEC said it does not intend to recommend enforcement action against the company at this time, while noting the notice should not be viewed as exoneration or a guarantee that no future action will result.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dr. Reddy's Laboratories Limited published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001575872-26-000078), on February 24, 2026, and is solely responsible for the information contained therein.